pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,189 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1884Endpoints1458Fierce Biotech773BioSpace762BioPharma Dive551raps253onclive165fda recalls
therapy area
allOncology12979Rare Disease3371Immunology3063Cardiology2861Hematology2315Pulmonology2256Vaccines
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 10h agoRegulatoryNegative↗ source
  • UnitedHealth sues CMS over lowered 2027 Medicare Advantage star ratings
    UnitedHealth Group has filed a lawsuit against the Centers for Medicare & Medicaid Services seeking to overturn the agency’s lowered star ratings for its Medicare Advantage plans for 2027. The sui…
    STAT · 2h agoRegulatoryNegative↗ source
← prev
page 1 of 208
next →
122
fda medwatch116
globenewswire health73
fda press62
1881
Psychiatry & CNS1235
Ophthalmology1140
Endocrinology & Metabolism809
Pain793
Nephrology788
  • Opinion: More surgeons in Africa isn’t enough when only 10% are women
    The systems built to grow global surgery are not required to measure the number of women surgeons.
    STAT · 41m ago↗ source
  • Opinion: More doctors should prescribe exercise after a concussion
    Nearly everyone caring for me had been trying to keep me safe. My ski instructor expected something hard of me. I needed both.
    STAT · 41m ago↗ source
  • FDA’s search for a new leader, and China’s largest drugmakers
    This week on "The Readout LOUD" podcast: the FDA is again searching for a new leader and a closely tracked lung cancer drug suffers an agency rejection.
    STAT · 41m ago↗ source
  • Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that
    Ian Burkhart, founder of a coalition of brain implant trial participants, says device developers should give patients more agency in research.
    STAT · 41m ago↗ source
  • FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravis
    The FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
    BioSpace · 19h agoApprovalPositive↗ source
  • US panel warns China’s biotech plan could dominate sector and threaten drug supply chain
    A congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…
    BioPharma Dive · 17h agoRegulatoryNegative↗ source
  • FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravis
    The Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
    BioPharma Dive · 19h agoApprovalPositive↗ source
  • FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapy
    The U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
    raps · 1d agoApprovalPositive↗ source
  • Congressional biotech panel cautions on rising China licensing deals
    A bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…
    Endpoints · 14h agoRegulatoryNegative↗ source
  • Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher disease
    Sanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…
    Endpoints · 14h agoApprovalPositive↗ source
  • Sanofi explores acquisition of Insmed in potential major biopharma deal
    Sanofi is reportedly evaluating a purchase of the U.S. drugmaker Insmed, according to a Bloomberg News report. The potential transaction would rank among the largest biopharma acquisitions in rece…
    Endpoints · 17h agoDealNeutral↗ source
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 19h agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 20h agoDealPositive↗ source
  • Merck teams with Isomorphic Labs to discover new oncology small-molecule candidates
    Merck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
    STAT · 22h agoDealPositive↗ source
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 1d agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 1d agoDealPositive↗ source
  • U.S. loses measles elimination status as outbreaks claim first deaths in decades
    The Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…
    STAT · 11h agoNegative↗ source
  • Study finds malaria antibody L9LS reduces vaccine response in infants
    Researchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
    STAT · 11h agoNegative readoutNegative↗ source
  • Sanofi receives FDA clearance for Infilbray, first pill to treat neurological symptoms of Type 3 Gaucher disease
    Sanofi received FDA clearance for Infilbray, a once-daily pill for Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. The drug, inherited from Sanofi’s 2011 acquisition…
    BioPharma Dive · 16h agoApprovalPositive↗ source
  • Eli Lilly breaks ground on $3.5 billion Pennsylvania plant to produce obesity drugs
    Eli Lilly has begun construction of a new manufacturing facility in the Lehigh Valley region of Pennsylvania. The $3.5 billion plant is slated to increase capacity for the company’s obesity drug po…
    Endpoints · 17h agoNeutral↗ source
  • Lawmakers push for stronger U.S. biotech support to stay ahead of China
    Members of the congressional Biotech Caucus told reporters that Washington must act quickly to boost the U.S. biotech sector and keep it ahead of China. They called for increased funding, streamli…
    STAT · 17h agoRegulatoryNeutral↗ source
  • Telehealth firms Hims & Hers and Noom launch prescription peptide programs after HHS rule change
    Telehealth companies Hims & Hers and Noom announced this week that they will begin prescribing peptide products to eligible patients, marking the first major consumer‑focused rollouts of such thera…
    STAT · 17h agoNeutral↗ source
  • Chinese AI lab MegaRobo secures almost $200 million in funding as Isomorphic strikes partnership with Merck
    Chinese AI and lab-automation company MegaRobo announced it has raised close to $200 million, according to a post on WeChat. The capital injection is intended to expand the firm’s artificial-intel…
    Endpoints · 17h agoDealPositive↗ source